Prognostic factors in de novo myelodysplastic syndrome in young and middle-aged people

Authors

  • Наталья Николаевна Климкович State Educational Institution «Belarusian Medical Academy of Post-Graduate Education» P. Brovki str, 3/3, Minsk, Republic of Belarus, 220013, Belarus
  • Ольга Владимировна Красько State Scientific Institution «United Institute of Informatics Problems of the National Academy of Sciences of Belarus» st. Surganova, 6, Minsk, Republic of Belarus, 220012, Belarus
  • Татьяна Ивановна Козарезова State Educational Institution «Belarusian Medical Academy of Post-Graduate Education» P.Brovki str, 3/3, Minsk, Republic of Belarus, 220013, Belarus

DOI:

https://doi.org/10.15587/2313-8416.2015.36499

Keywords:

myelodysplastic syndromes, prognosis, expression CD95 and FLT3

Abstract

We spent multivariate analysis of clinical and laboratory parameters for the prediction of de-novo myelodysplastic syndromes (MDS) patients aged 18-60 years. The results of clinical application of prognostic systems in MDS show that there is a large variability within individual risk groups, especially at low-risk MDS. So now hematologists conduct research aimed at identifying additional adverse risk MDS. This is done so that patients with low-risk MDS embodiments and unfavorable prognosis could benefit from early therapeutic intervention, and not only be clinician monitored until disease progression. We found that additional adverse risk factors for the development of MDS are the expression of CD95 in bone marrow ≤40 % and FLT3≥60 %. The expression level of CD95 in bone marrow cells≤40 % and FLT3≥60 % can be considered as a prognostic marker progression of MDS and time start specific therapy

Author Biographies

Наталья Николаевна Климкович, State Educational Institution «Belarusian Medical Academy of Post-Graduate Education» P. Brovki str, 3/3, Minsk, Republic of Belarus, 220013

PhD, Associate Professor

Department of Pediatric Oncology and Hematology

Ольга Владимировна Красько, State Scientific Institution «United Institute of Informatics Problems of the National Academy of Sciences of Belarus» st. Surganova, 6, Minsk, Republic of Belarus, 220012

PhD, Associate Professor

Laboratory of Bioinformatics

Татьяна Ивановна Козарезова, State Educational Institution «Belarusian Medical Academy of Post-Graduate Education» P.Brovki str, 3/3, Minsk, Republic of Belarus, 220013

Professor

Department of Pediatric Oncology and Hematology

References

Kosmider, O., Gelsi-Boyer, V., Cheok, M. et al. (2009). TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes. Blood, 114 (15), 3285–3291. doi: 10.1182/blood-2009-04-215814

Kjeldsen, L., Dybedal, I., Hellström-Lindberg, E. et al. (2010). Guidelines for the diagnosis and treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia. Nordic MDS Group. MDS Guideline Programme, 5, 4th update, 43.

Malcovati, L., Porta, M. G., Pascutto, C. et al. (2005). Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. Journal of Clinical Oncology, 23 (30), 7594–7603. doi: 10.1200/jco.2005.01.7038

Malcovati, L., Germing, U., Kuendgen, A. et al. (2008). Time-Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes. Journal of Clinical Oncology, 25 (23), 3503–3510 doi: 10.1200/jco.2006.08.5696

Weinberg, O. K., Seetharam, M., Ren, L. et al. (2009). Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. Blood, 113 (9), 1906–1908. doi: 10.1182/blood-2008-10-182782

Cazzola, M. (2011). Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Haematology, 96 (3), 349–352. doi: 10.3324/haematol.2010.030023

Alessandrino, E. P., Della Porta, M. G., Bacigalupo, A. et al. (2008). WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood, 112 (3), 895–902. doi: 10.1182/blood-2008-03-143735

Greenberg, P., Cox, C., LeBeau, M. M. et al. (1997). International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89 (6), 2079–2088.

Greenberg, P. L., Tuechler, H., Schanz, J. et al. (2012). Revised International prognostic scoring system for myelodysplastic syndromes. Blood, 120 (12), 2454–2465. doi: 10.1182/blood-2012-03-420489

Therneau, T. (2014). A Package for Survival Analysis in S. R package version 2.37-7. Available at: http://CRAN.R-project.org/package=survival (Last accessed: 15-09-2014).

R: A language and environment for statistical computing. R Foundation for Statistical Computing/R Core Team (2013). Vienna, Austria. Available at: http://www.R-project.org/

Brunning, R. D., Orazi, A., Germing, U. et al.; Swerdlow, S. H., Campo, E., Harris, N. L. et al. (Eds.) (2008). Myelodysplastic syndromes/neoplasms, overview. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC, 88–93.

Published

2015-01-27

Issue

Section

Medical